|
Today's Headlines
Patients who experience a warfarin-associated gastrointestinal tract bleeding event should resume anticoagulation therapy during the 90 days following the event to decrease the risk of thrombosis and death, according to a study published online in the Archives of Internal Medicine. » Full article
|
|
Patients with breakthrough cancer pain may want to consider intranasal fentanyl spray over oral agents to treat their breakthrough pain because of improved onset of analgesia and avoidance of nausea and vomiting, according to a report published online for The Annals of Pharmacotherapy. » Full article
|
|
Apixaban (Eliquis), an investigational anticoagulant developed by Bristol-Myers Squibb and Pfizer, has lower rates of stroke, systemic embolism, and bleeding than warfarin in patients with atrial fibrillation, regardless of level of risk for these events, according a recent online analysis published October 2 in The Lancet. » Full article
|
|
Use of concurrent sedating agents provides rapid sedation and reduces the need for resedation in acutely agitated patients, according to clinical trial results published online in the Annals of Emergency Medicine. » Full article
|
|
CONTINUING EDUCATION
Welcome to the second activity of our new CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 CPE credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The October activity will cover medical nutrition therapy, physical activity, and health maintenance considerations for patients with diabetes. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
Through the use of its electronic health records (EHRs), a simvastatin prescribing guide was implemented at the Mayo Clinic in response to FDA's recommendation to limit the use of the 80-mg dose of the drug. A formulary decision process led to the Mayo Clinic abandoning the use of simvastatin 80 mg daily and developing conversion charts and case examples to help prescribers understand the options for individual patients, said R. Scott Wright, MD, at the American College of Cardiology's 61st Annual Scientific Session & Expo in Chicago. » Full article
|
Survey
a) Hardly ever
b) Once a week
c) Once a month
d) Once a day
Respond here and see what your colleagues think too.Want to see the results of our last survey. Click here.
|
|
|
Like
Tweet
